Cholangiocarcinoma News

June 2023, Vol 4, No 2

Annual CCF Conference Brings Together All Stakeholders
By Milind M. Javle, MD
Letter from the Editor-in-Chief
June 2023, Vol 4, No 2
This issue of CCA News highlights the Cholangiocarcinoma Foundation (CCF) 10th Annual Conference held in April. This meeting was chaired by Dr Chiara Branconi, a Lord Kelvin Adam Smith Reader at the University of Glasgow and a medical oncologist with Beatson Cancer Centre; and Dr Laura Goff, medical director of the Vanderbilt-Ingram Cancer Center’s Hematology and Oncology Division.
Read More
Importance of Proper Nutrition in Patients With Cholangiocarcinoma
CCF Highlights
June 2023, Vol 4, No 2
A specialist in oncology nutrition and the caregiver of a patient with cholangiocarcinoma discuss the importance of proper nutrition in achieving positive cancer outcomes.
Read More
10th Annual Cholangiocarcinoma Foundation Conference: International Collaboration, Patient Connections, Industry Updates
CCF Corner
June 2023, Vol 4, No 2
Cancer investigators and clinicians from around the world connected with patients, caregivers, and industry officials at the foundation’s conference in Salt Lake City, UT.
Read More
Encourage Your Patients to Participate! Actively Recruiting US-Based Clinical Trials in CCA
New Feature
June 2023, Vol 4, No 2
This new CCA News feature aims to provide an ongoing list of US-based clinical trials that are actively recruiting for clinicians to use in discussions with their patients to encourage enrollment.
Read More
Combined Hepatocellular Cholangiocarcinoma
By Jennifer J Knox, MD, MSc, FRCPC; Gordon T Moffat, MD, FRCPC
From the Advisory Board
June 2023, Vol 4, No 2
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a unique malignancy comprised of both hepatocellular carcinoma (HCC) from hepatocytes and cholangiocarcinoma (CCA) from bile duct epithelial cells within the same tumor. Initially thought to be a rare entity, the incidence is increasing (up to 14%), yet recognition remains low.
Read More
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
CCF Highlights
June 2023, Vol 4, No 2
Dr Rachna Shroff and Dr Madhulika Eluri debated whether it is time to move away from chemotherapy as a mainstay in the treatment of cholangiocarcinoma.
Read More
Incorporating ctDNA Into Clinical Trial Design
CCF Highlights
June 2023, Vol 4, No 2
Cholangiocarcinoma experts discussed potential applications of liquid biopsies using circulating tumor DNA.
Read More
Harnessing the Microbiome to Optimize Response to Immunotherapy
CCF Highlights
June 2023, Vol 4, No 2
Dr Marina Barcena-Varela described a study that aims to understand how the microbiome affects cholangiocarcinoma tumorigenesis based on genetic alterations and response to targeted and immunotherapy.
Read More
New Treatment Strategy for FGFR2 Fusion–Positive CCA
CCF Highlights
June 2023, Vol 4, No 2
Dr Michael E. Lidsky described a novel investigative murine model of FGFR2 fusion–positive intrahepatic cholangiocarcinoma and how it may enhance treatment outcomes.
Read More
CDX-1140 Plus Capecitabine, Oxaliplatin, and Pembrolizumab in Advanced BTC
CCF Highlights
June 2023, Vol 4, No 2
Dr Cecilia Monge presented the rationale and study design for a new phase 2 study investigating the CD40 agonist CDX-1140 in combination with capecitabine, oxaliplatin, and pembrolizumab in advanced biliary tract cancer.
Read More

Page 1 of 2

  • 1
  • 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly CCA News print publication and CCA News weekly e‑newsletter.

© Amplity Health. All Rights Reserved. Privacy Policy.